Verici Dx plc (LON:VRCI – Get Free Report) fell 8.1% on Thursday . The company traded as low as GBX 0.62 and last traded at GBX 0.62. 677,517 shares were traded during trading, a decline of 56% from the average session volume of 1,522,965 shares. The stock had previously closed at GBX 0.68.
Verici Dx Price Performance
The company has a 50 day moving average of GBX 0.75 and a 200 day moving average of GBX 0.69. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.64. The firm has a market cap of £9.85 million, a price-to-earnings ratio of -0.22 and a beta of 1.59.
About Verici Dx
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Further Reading
- Five stocks we like better than Verici Dx
- Did you hear what Nvidia’s CEO said?
- Think You Missed Silver? You’re Wrong. Here’s Why.
- How Long Does $2.5M Last in Retirement?
- Your Bank Account Is No Longer Safe
- Huge robotics rollout underway
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
